Recently, the China National Accreditation Service for Conformity Assessment (CNAS) dispatched a specialist group to conduct on-site evaluations for Laviana Pharma (Tianjin) Company's Testing Center in relation to its re-assessment and expansion of scope. Laviana Pharma CTO Zhang Haijun, General Manager Jin Jing of Tianjin Branch, CMC Director Hao Yanshan, and other leaders attended the assessment meeting.
During the assessment period, the expert panel conducted a comprehensive on-site evaluation of Laviana Pharma (Tianjin) Co., Ltd.'s testing center. The expert panel found that Laviana Pharma (Tianjin) Company's Laboratory Management System, Quality Assurance, Technical Capabilities, and so on, met all the requirements for CNAS accreditation criteria. They recommended maintaining the laboratory's accredited status and all approved methods and parameters, while also suggesting the addition of new expanded parameters (Drug Detection – X-ray Diffraction Method).
It is worth mentioning that Laviana Pharma (Tianjin) Company's Testing Center has an international team with professional experience in drug discovery. The center offers a range of services, including route development for innovative drugs and intermediates, custom synthesis, process development and optimization, formulation research, quality research, and method validation.
This successful evaluation is a testament to our Testing Center's consistent adherence to high standards and rigorous requirements over an extended period. We will take advantage of this opportunity to continuously strengthen our internal management, enhance our technical capabilities, and provide more accurate and efficient services in the field of detection. The addition of CNAS accreditation for our testing center and the expansion of testing parameters will further enhance our market competitiveness, supporting our growth in the pharmaceutical industry.